These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286 [TBL] [Abstract][Full Text] [Related]
24. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538 [TBL] [Abstract][Full Text] [Related]
25. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Cox R; Epstein JI Am J Surg Pathol; 2011 Sep; 35(9):1337-42. PubMed ID: 21836490 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection. Chang WC; Chang YH; Pan CC Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706 [TBL] [Abstract][Full Text] [Related]
27. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients. Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551 [TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth. Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613 [TBL] [Abstract][Full Text] [Related]
29. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma]. Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079 [TBL] [Abstract][Full Text] [Related]
30. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808 [TBL] [Abstract][Full Text] [Related]
32. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461 [TBL] [Abstract][Full Text] [Related]
33. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains. Tamas EF; Epstein JI Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480 [TBL] [Abstract][Full Text] [Related]
34. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Compérat E; Camparo P; Haus R; Chartier-Kastler E; Radenen B; Richard F; Capron F; Paradis V Virchows Arch; 2007 Apr; 450(4):419-24. PubMed ID: 17333265 [TBL] [Abstract][Full Text] [Related]
35. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040 [TBL] [Abstract][Full Text] [Related]
36. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Kunju LP; Lee CT; Montie J; Shah RB Pathol Int; 2005 May; 55(5):248-54. PubMed ID: 15871722 [TBL] [Abstract][Full Text] [Related]
37. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225 [TBL] [Abstract][Full Text] [Related]
38. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Wasco MJ; Daignault S; Bradley D; Shah RB Hum Pathol; 2010 Feb; 41(2):163-71. PubMed ID: 19800100 [TBL] [Abstract][Full Text] [Related]
39. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Burger M; Denzinger S; Hartmann A; Wieland WF; Stoehr R; Obermann EC Br J Cancer; 2007 Jun; 96(11):1711-5. PubMed ID: 17505513 [TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]